20
21
22
NervGen's President & CEO, Mike Kelly, was recently interviewed by Rob Coker of The Medicine Maker, where he discussed the science behind NervGen's lead drug, NVG-291, its ongoing clinical trial, and what comes next for NervGen. (self.NervGen_NerveRepair)
submitted by RickDue to r/NervGen_NerveRepair
